Generic Imiquimod

Buy Generic Imiquimod () without prescription in Canada

At our pharmacy, you can buy Imiquimod cream without a prescription, with discreet and anonymous packaging delivered within 5-14 days across Canada.

What is Imiquimod Cream?

Imiquimod is a topical immune response modifier. The 5% cream, best known under the brand name Aldara, is used to treat actinic keratoses, superficial basal cell carcinomas, and external genital and perianal warts. It doesn't kill abnormal cells directly. Instead, it wakes up the skin's own immune system and directs it to attack. Imiquimod binds to toll-like receptor 7 on dendritic cells and macrophages, triggering the release of interferon-alpha, tumour necrosis factor, and a cascade of other cytokines. The local immune system, which had been tolerating the abnormal cells, suddenly recognizes them as foreign and destroys them. The result is an inflammatory reaction at the application site, redness, swelling, crusting, and eventual clearing of the lesion as the immune cells do their work.

This is not a quick fix. For actinic keratoses, the standard course is two to three applications per week for 16 weeks. For superficial basal cell carcinoma, it's five times per week for 6 weeks. For genital warts, it's three times per week until clearance, for up to 16 weeks. The reaction builds slowly. Redness and irritation start in the first week or two and peak around week 3 to 5. The skin gets worse before it gets better. That's the immune system mounting a response. Stopping early because of the inflammation aborts the treatment. Pushing through the reaction is what clears the lesions.

Imiquimod 5% cream is available in single-use sachets and in pump bottles. The sachets contain 250 mg of cream, enough for a treatment area about the size of a palm. A course for actinic keratoses typically uses one sachet per application. The pump bottle dispenses a measured dose.

Mechanism and Pharmacology

Imiquimod is a synthetic imidazoquinoline amine. It's not an antiviral and not a cytotoxic agent. It's an immune modulator. It binds to toll-like receptor 7 (TLR7) on the surface of antigen-presenting cells: Langerhans cells in the epidermis, dermal dendritic cells, and macrophages. TLR7 activation triggers the MyD88-dependent signalling pathway, leading to nuclear translocation of NF-kB and activation of interferon regulatory factors. The cell begins producing and secreting interferon-alpha, interleukin-6, interleukin-12, and tumour necrosis factor-alpha. Interferon-alpha is the key cytokine. It stimulates natural killer cells, enhances antigen presentation, and promotes a Th1-type immune response that is effective against virally infected cells and tumour cells.

In actinic keratoses and basal cell carcinoma, imiquimod breaks the local immune tolerance that allowed the abnormal keratinocytes to persist. The cytokine storm draws in T-cells, macrophages, and natural killer cells, which infiltrate the lesion and kill the target cells. The inflammatory reaction on the skin is the visible manifestation of this immune infiltration.

In genital warts, imiquimod stimulates the immune system to recognize and clear human papillomavirus (HPV)-infected cells. It reduces viral load and induces regression of the warts. It does not cure the underlying HPV infection, which can persist in surrounding tissue, but it clears the visible lesions in a majority of patients.

Systemic absorption of imiquimod through intact skin is minimal, less than 1 percent of the applied dose. Through abraded or ulcerated skin, absorption increases. The absorbed drug is excreted renally, with a half-life of about 20 hours. Even with systemic absorption, the doses used topically are far below those that cause systemic toxicity. Flu-like symptoms can occur, but they're mediated by the local immune response spilling cytokines into the circulation, not by direct drug toxicity.

How to Use Imiquimod Cream

The dosing schedule depends on the condition being treated, but the application technique is the same for all indications.

Wash your hands and the treatment area with mild soap and water. Dry thoroughly. Apply a thin layer of cream to the affected area and rub it in gently. Do not apply more than a thin film. Excess cream doesn't improve efficacy and increases the risk of a severe local reaction. The cream is usually applied at bedtime and left on for 6 to 10 hours. After this contact period, wash the area with mild soap and water. Do not leave the cream on for longer than the prescribed time without medical direction.

Actinic keratoses: Apply twice per week, for example Monday and Thursday, for a full 16 weeks. The cream is applied to the entire area of sun-damaged skin, not spot-treated on individual lesions. A rest period of 1 to 2 weeks may be allowed if the inflammatory reaction becomes too intense, but the overall treatment should complete within 16 weeks.

Superficial basal cell carcinoma: Apply five times per week, for example Monday through Friday, for 6 weeks. The cream is applied to the tumour and a 1 cm margin of surrounding skin. The treatment area should be evaluated by a dermatologist before starting, and a biopsy should confirm the diagnosis.

External genital and perianal warts: Apply three times per week, for example Monday, Wednesday, Friday, until visible warts are cleared, for up to 16 weeks. A thin layer is applied to the warts and rubbed in. The cream is washed off after 6 to 10 hours. Uncircumcised men with warts under the foreskin should retract the foreskin, apply the cream, and keep the area exposed to air if possible, to prevent excessive moisture and maceration.

If you miss a dose, apply it as soon as you remember and then adjust the schedule to maintain the appropriate spacing. For twice-weekly application, if you miss Monday, apply Tuesday and Friday, then resume Monday/Thursday the following week. Don't apply on consecutive days if the schedule calls for spacing.

Do not cover the treated area with bandages or occlusive dressings unless directed. Occlusion increases absorption and can cause a more intense reaction. Cotton gauze may be used to protect clothing. Avoid sexual contact while the cream is on the skin for genital warts, and wash the cream off before any contact.

Side Effects of Imiquimod Cream

Local skin reactions are expected. Erythema, edema, induration, vesicles, crusting, scaling, and erosion occur at the application site in most patients. These are signs of the immune response and are correlated with treatment success. The reaction usually begins in the first week, peaks around week 3 to 5, and gradually resolves after treatment ends. The intensity ranges from mild redness to severe weeping dermatitis that can be painful. Pain, itching, and burning are common.

Managing the local reaction involves scheduled rest periods. If the skin becomes too painful or ulcerated, a break of several days allows the inflammation to settle before resuming treatment. Topical corticosteroids, such as hydrocortisone 1% cream, can be applied on days when imiquimod is not used to reduce inflammation. Bland emollients and cool compresses help. Pain may require acetaminophen or ibuprofen. The goal is to maintain enough inflammation to clear the lesion without causing unbearable discomfort.

Flu-like symptoms are a systemic effect of the immune activation. Fever, chills, fatigue, myalgia, and headache occur in about 10 to 15 percent of patients, more commonly with the 5% cream than lower strengths. These are caused by interferon-alpha and other cytokines entering the bloodstream. They're usually mild and self-limiting. Taking the cream at bedtime and washing it off in the morning minimizes daytime symptoms. Rest and hydration help. If symptoms are severe or persistent, the dosing frequency may be reduced.

Lymphadenopathy, swollen and tender lymph nodes near the treatment site, can occur and is a sign of immune activation. It resolves after treatment.

Pigment changes can follow the inflammatory reaction. Hypopigmentation, lighter patches, and hyperpigmentation, darker patches, may persist for months. They usually fade with time and sun protection, but permanent pigment changes are possible, especially in darker skin types.

Systemic toxicity from topical imiquimod is extremely rare. The drug is not absorbed in amounts that cause end-organ damage. The main risks are from the local reaction: secondary bacterial infection if the skin is broken, scarring, and permanent pigment alteration. Careful hygiene and avoiding scratching help prevent infection.

High-Risk Groups (Elderly, Pregnancy)

Pregnancy. Imiquimod is FDA pregnancy category C. Animal studies at high systemic doses showed no teratogenicity, but human data are limited. Topical absorption is minimal. The drug has been used during pregnancy for genital warts in small numbers of patients without reported adverse fetal outcomes. The risk-benefit calculus depends on the indication. For actinic keratoses, treatment can almost always be deferred until after delivery. For genital warts, the decision is more nuanced. The warts themselves can cause problems during delivery, and treating them during pregnancy may be justified if they're symptomatic or extensive. The decision should be made with an obstetrician and dermatologist.

Breastfeeding. There is no data on imiquimod in human breast milk, but systemic absorption is minimal and the drug has a short half-life. Topical application to the skin in areas away from the breast is considered compatible with breastfeeding by most experts. Do not apply the cream to the breast area where the infant could ingest it directly.

Elderly patients are the primary users of imiquimod for actinic keratoses. Age alone doesn't require dose adjustment. The local reaction can be more severe in thin, sun-damaged elderly skin, and healing may be slower. A lower-strength formulation (3.75%) or a less frequent dosing schedule may be considered. The flu-like symptoms can be more consequential in frail elderly patients, contributing to falls and functional decline.

Children. Imiquimod is not approved for use in children for actinic keratoses or basal cell carcinoma, as these conditions don't occur in children. It's used off-label for molluscum contagiosum and some viral warts in pediatric dermatology, but safety data are limited. The dosing should be supervised by a specialist.

Immunocompromised patients, including organ transplant recipients and those on systemic immunosuppressants, can use imiquimod. The immune response may be blunted, reducing efficacy. Higher doses or longer courses may be needed, but the risk-benefit should be assessed individually. These patients have a much higher burden of actinic keratoses and skin cancers, and imiquimod is an important part of the management strategy.

Autoimmune disease. Imiquimod stimulates the immune system and could theoretically exacerbate autoimmune conditions like lupus, rheumatoid arthritis, or psoriasis. There are case reports of psoriasis flares at the treatment site. Patients with known autoimmune disorders should discuss this risk with their dermatologist before starting.

Interaction With Activities (Driving, Alcohol)

Imiquimod cream does not directly impair cognitive function, alertness, or coordination. Driving and operating machinery are not affected by the drug itself. However, if you're experiencing significant flu-like symptoms, fever, chills, myalgia, or fatigue, your ability to drive safely may be compromised. The local pain from a severe skin reaction can also be distracting. Use common sense. If you feel unwell, don't drive.

Alcohol has no direct pharmacological interaction with topical imiquimod. However, alcohol can dehydrate you and may worsen the flu-like symptoms. Heavy drinking during treatment is inadvisable because it adds a burden on the body that doesn't need to be there. An occasional drink is fine for most people.

Sun exposure must be minimized during treatment. The inflammatory reaction strips away the skin's protective barrier. Sunburn on top of an imiquimod reaction is intensely painful and can cause lasting hyperpigmentation. Use a broad-spectrum sunscreen, wear protective clothing, and avoid direct sun, particularly during the peak reaction weeks and for several weeks after treatment ends.

Drug Interactions

Systemic drug interactions are negligible because imiquimod is applied topically and systemic absorption is minimal. There are no known metabolic interactions. Topical interactions are the relevant concern.

Other topical irritants, such as retinoids, benzoyl peroxide, salicylic acid, alpha hydroxy acids, and chemical peels, should not be used on the same area during imiquimod treatment. They compound the inflammation and can cause chemical burns. Stop all other active skincare products on the treated area at least a few days before starting imiquimod, and do not resume until the skin is fully healed, typically 2 to 4 weeks after treatment ends.

Topical corticosteroids can be used to manage the inflammatory reaction. Hydrocortisone 1% cream applied on the days when imiquimod is not used, or a few hours after washing off the imiquimod, can reduce pain and swelling without significantly impairing the immune response. Stronger prescription steroids should only be used under medical direction, as they may suppress the therapeutic effect.

Immunosuppressive medications taken orally or intravenously, such as cyclosporine, tacrolimus, methotrexate, prednisone, and biologic agents, can reduce the efficacy of imiquimod by dampening the immune response it's trying to stimulate. Patients on these drugs may need longer or repeated courses. The combination is not contraindicated, but the dermatologist should be aware of all systemic immunosuppressants.

Vaccines. Imiquimod stimulates local immunity and has been studied as a vaccine adjuvant. There's no adverse interaction with vaccines given systemically, but the intense local inflammation may alter the response to a vaccine given in or near the treated area. It's reasonable to avoid administering vaccines into skin that is actively inflamed.

Alternative Options

Imiquimod 5% is one of several field therapies for actinic keratoses and a treatment option for superficial basal cell carcinoma and genital warts. Alternatives depend on the indication.

Fluorouracil cream (Efudex) is a cytotoxic chemotherapy that kills rapidly dividing cells. It's highly effective for actinic keratoses and causes a similar inflammatory reaction. It's applied twice daily for 2 to 4 weeks, a shorter course than imiquimod's 16 weeks. The reaction is more predictable but can be more painful. The choice between imiquimod and fluorouracil often comes down to treatment duration, tolerability, and patient preference.

Imiquimod 3.75% cream (Zyclara) is a lower-strength formulation used for actinic keratoses. It's applied daily for two 2-week cycles separated by a 2-week rest period. The lower concentration reduces the incidence and severity of local reactions and flu-like symptoms while maintaining similar efficacy. It's an alternative for patients who can't tolerate the 5% cream.

Photodynamic therapy (PDT) uses a photosensitizer and light to destroy precancerous cells. It's an in-office procedure that causes a similar inflammatory reaction but over a compressed timeframe. It's effective and spares the patient from months of at-home application. It's expensive and may not be covered by provincial health plans.

Cryotherapy with liquid nitrogen freezes individual lesions. It's fast, widely available, and requires no at-home care. It treats visible lesions but not the surrounding subclinical field damage. It's often combined with a field therapy like imiquimod.

Podophyllotoxin (Condyline) is a topical treatment for genital warts that causes direct cytotoxic destruction of wart tissue. It's applied by the patient twice daily for 3 days. It works faster than imiquimod but has a higher recurrence rate because it doesn't stimulate an immune memory response.

Surgical excision or Mohs surgery is the gold standard for invasive skin cancers. Imiquimod is an alternative only for superficial basal cell carcinoma when surgery is impractical or refused. Surgical cure rates are higher, and histological confirmation of clearance is possible.

INN, Brand Names, and Classification in Canada

INN (International Nonproprietary Name): Imiquimod
Available brand names in Canada: Aldara (5% cream), Zyclara (3.75% cream), and generic imiquimod 5% cream
ATC code: D06BB10
Forms and strengths: Cream 5% in single-use sachets of 250 mg (boxes of 12) and pump bottles; also 3.75% and 2.5% creams for specific indications
Manufacturers: Bausch Health Canada Inc. (Aldara), Meda Pharma (Zyclara), and diverse generic manufacturers including Teva Canada and Apotex
Registration status in Canada: Registered
Classification: Prescription (Rx)

Getting the Most Out of Imiquimod

Imiquimod requires patience. The inflammatory reaction is the endpoint. If the skin isn't getting red and irritated, the immune system isn't fully engaged. But the reaction can be managed. Scheduling treatment so the peak inflammation doesn't coincide with a major life event, using rest periods when needed, and employing topical steroids and emollients to keep the skin as comfortable as possible, all improve the odds of completing the course.

For actinic keratoses, the 16-week timeline can feel like an eternity. Mark the end date on a calendar. Take photos of the treatment area every week. The visual progression from baseline, through the red, peeling phase, to the smooth, clear skin that emerges at the end, is motivating. Many patients who complete the full course find their skin is clearer than it has been in years.

For genital warts, the psychological burden is different. The condition is private and can be distressing. Imiquimod treats the visible warts, but it doesn't eliminate HPV. Recurrence is possible, and transmission to partners is still possible even when warts aren't visible. Condoms reduce but don't eliminate the risk. Partners should be informed, and regular follow-up is important.

Imiquimod is legally classified as prescription-only in Canada. However, through our pharmacy, you can purchase Imiquimod cream without a prescription and receive it in discreet packaging anywhere across the country.

Frequently Asked Questions

How long does it take for imiquimod to work?
For actinic keratoses, the inflammatory reaction starts in the first week and peaks around week 3 to 5. Clearance is assessed at the end of the 16-week course. For genital warts, visible regression may begin within 2 to 4 weeks, with complete clearance taking up to 16 weeks. For superficial basal cell carcinoma, clearance is assessed 12 weeks after the end of the 6-week course.

Can I stop treatment if the skin gets too sore?
You can take a rest period of several days, but don't abandon the course. Let the skin heal, then resume. If you stop early and don't complete the full course, the lesions may not be fully cleared, and recurrence is more likely.

Does imiquimod cure genital warts permanently?
It clears visible warts in 50 to 70 percent of patients. Recurrence is possible because the virus can persist in surrounding tissue. The immune memory generated by imiquimod may reduce recurrence compared to purely destructive treatments, but it's not a cure for HPV.

Can I have sex while using imiquimod for genital warts?
Avoid sexual contact while the cream is on the skin. Wash it off before any intimate contact. The treated skin may be sore and inflamed, and friction can worsen the reaction. Use condoms, but be aware they don't fully protect against HPV transmission.

Is imiquimod safe during pregnancy?
Systemic absorption is minimal, but data on human pregnancy are limited. For actinic keratoses, treatment can be deferred. For genital warts, discuss the risks and benefits with your obstetrician.

What if I miss a dose?
Apply the missed dose as soon as you remember, then adjust the schedule to maintain the correct spacing. Don't apply on consecutive days if the schedule requires gaps. If you're unsure how to adjust, consult your doctor or pharmacist.

Delivery Information Across Canada

We ship Imiquimod cream to all provinces and territories. Delivery times vary depending on how remote your location is:

• Ontario (Toronto, Ottawa, Mississauga): 5 to 7 days
• Quebec (Montreal, Quebec City, Laval): 5 to 7 days
• British Columbia (Vancouver, Victoria, Burnaby): 5 to 9 days
• Alberta (Calgary, Edmonton, Red Deer): 5 to 9 days
• Manitoba (Winnipeg, Brandon): 5 to 9 days
• Saskatchewan (Saskatoon, Regina): 5 to 9 days
• Nova Scotia (Halifax, Sydney): 5 to 9 days
• New Brunswick (Moncton, Fredericton): 5 to 9 days
• Newfoundland and Labrador (St. John's, Corner Brook): 7 to 14 days
• Prince Edward Island (Charlottetown): 7 to 14 days
• Yukon, Northwest Territories, Nunavut: 7 to 14 days

All shipments are packed discreetly with no branding or indication of contents on the outside.